Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies

BACKGROUND: Immunotherapy with monoclonal antibodies that target amyloid beta has been under investigation as a treatment for patients with Alzheimer’s disease (AD). The 3000 and 3001 phase 3 clinical studies of intravenous bapineuzumab assessed safety and efficacy in patients with mild to moderate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Alzheimers Res Ther
Main Authors: Ivanoiu, Adrian, Pariente, Jérémie, Booth, Kevin, Lobello, Kasia, Luscan, Gerald, Hua, Lisa, Lucas, Prisca, Styren, Scot, Yang, Lingfeng, Li, David, Black, Ronald S., Brashear, H. Robert, McRae, Thomas
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4918115/
https://ncbi.nlm.nih.gov/pubmed/27334799
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-016-0193-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados